Complex Generics Pipeline
Mayne Pharma continues to expand its generic portfolio through internal formulation R&D and strategic partnerships focusing on targeting complex solid oral and alternate dosage forms.
Mayne Pharma is one of a few pharmaceutical companies that has integrated scientific expertise across generic and novel formulation R&D. Mayne Pharma’s R&D team leverages ideas from its scientists in Australia and the US to identify new product opportunities that may lead to better and more accessible medicines for patients globally.
Our internal development capabilities include oral solid and topical dosage forms, including those of poorly soluble compounds, and these capabilities have been complemented through external strategic alliances with best-in-class pharmaceutical developers and manufacturers.
This generic pipeline includes products under development and under review at the FDA across a broad range of therapeutic areas and dosage forms.